ZA200606870B - Oxadiazolone derivatives as PPAR delta agonists - Google Patents
Oxadiazolone derivatives as PPAR delta agonists Download PDFInfo
- Publication number
- ZA200606870B ZA200606870B ZA200606870A ZA200606870A ZA200606870B ZA 200606870 B ZA200606870 B ZA 200606870B ZA 200606870 A ZA200606870 A ZA 200606870A ZA 200606870 A ZA200606870 A ZA 200606870A ZA 200606870 B ZA200606870 B ZA 200606870B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkylen
- formula
- compounds
- alkyl
- bond
- Prior art date
Links
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical class O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 title description 4
- 108010015181 PPAR delta Proteins 0.000 title description 3
- 239000000556 agonist Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 53
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 33
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 23
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
- 229910020008 S(O) Inorganic materials 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 claims description 3
- -1 O-phenyl Chemical group 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000003959 neuroinflammation Effects 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000004129 fatty acid metabolism Effects 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04007879A EP1586573B1 (en) | 2004-04-01 | 2004-04-01 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200606870B true ZA200606870B (en) | 2008-04-30 |
Family
ID=34924545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200606870A ZA200606870B (en) | 2004-04-01 | 2006-08-15 | Oxadiazolone derivatives as PPAR delta agonists |
Country Status (38)
Country | Link |
---|---|
US (3) | US20070179191A1 (sr) |
EP (3) | EP1586573B1 (sr) |
JP (1) | JP2007530612A (sr) |
KR (1) | KR20060135857A (sr) |
CN (1) | CN100582104C (sr) |
AR (1) | AR050576A1 (sr) |
AT (1) | ATE435225T1 (sr) |
AU (1) | AU2005231916A1 (sr) |
BR (1) | BRPI0509517A (sr) |
CA (1) | CA2561627A1 (sr) |
CR (1) | CR8572A (sr) |
CY (1) | CY1109370T1 (sr) |
DE (2) | DE602004004631D1 (sr) |
DK (1) | DK1740583T3 (sr) |
DO (1) | DOP2005000051A (sr) |
EC (1) | ECSP066892A (sr) |
ES (1) | ES2329484T3 (sr) |
GT (1) | GT200500028A (sr) |
HK (1) | HK1100408A1 (sr) |
HR (1) | HRP20090493T1 (sr) |
IL (1) | IL178056A0 (sr) |
MA (1) | MA28495B1 (sr) |
MY (1) | MY142431A (sr) |
NO (1) | NO20064981L (sr) |
PA (1) | PA8628701A1 (sr) |
PE (1) | PE20060323A1 (sr) |
PL (1) | PL1740583T3 (sr) |
PT (1) | PT1740583E (sr) |
RS (1) | RS51186B (sr) |
RU (1) | RU2374243C2 (sr) |
SI (1) | SI1740583T1 (sr) |
SV (1) | SV2006002071A (sr) |
TN (1) | TNSN06317A1 (sr) |
TW (1) | TW200602342A (sr) |
UA (1) | UA84203C2 (sr) |
UY (1) | UY28837A1 (sr) |
WO (1) | WO2005097786A1 (sr) |
ZA (1) | ZA200606870B (sr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060017929A (ko) * | 2004-08-04 | 2006-02-28 | 동화약품공업주식회사 | 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물 |
WO2007039176A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Derivatives of 2 -aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals |
BRPI0616465A2 (pt) | 2005-09-29 | 2011-06-21 | Sanofi Aventis | derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica |
JP2009509988A (ja) | 2005-09-29 | 2009-03-12 | サノフィ−アベンティス | フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用 |
ES2399147T3 (es) | 2006-09-08 | 2013-03-26 | Rhode Island Hospital | Tratamiento, prevención y reversión de una enfermedad hepática alcohólica |
JP2010502719A (ja) | 2006-09-08 | 2010-01-28 | ロード アイランド ホスピタル | アルコール誘発性脳疾患の治療、予防および回復 |
EP1932843A1 (en) | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
CN102056921A (zh) | 2008-06-09 | 2011-05-11 | 赛诺菲-安万特 | 首基为噁二唑酮的增环化n-杂环磺酰胺、其制备方法及其作为药物的用途 |
WO2010000353A1 (en) * | 2008-06-09 | 2010-01-07 | Sanofi-Aventis | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
WO2009149819A1 (en) * | 2008-06-09 | 2009-12-17 | Sanofi-Aventis | Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
EP2349285B1 (en) | 2008-10-10 | 2016-03-23 | Dara Biosciences, Inc. | Nanoemulsions comprising Spicamycin derivatives for use in the treatment of pain |
CN106243100B (zh) * | 2008-10-10 | 2019-04-09 | Vm生物医药公司 | 治疗酒精使用障碍,疼痛和其他疾病的药物组合与方法 |
CA2770405C (en) * | 2009-08-05 | 2015-03-17 | Daiichi Sankyo Company, Limited | Sulfone derivative |
MX2012001107A (es) * | 2009-08-05 | 2012-03-26 | Daiichi Sankyo Co Ltd | Derivado de amida. |
WO2015061481A1 (en) | 2013-10-23 | 2015-04-30 | Dara Biosciences, Inc. | Methods of treating liquid tumors using compositions comprising spicamycin derivatives |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256680A (en) * | 1988-11-29 | 1993-10-26 | Warner-Lambert Company | 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents |
FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
JP3144624B2 (ja) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
CA2241567A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
HU227021B1 (en) | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
HUP0301101A3 (en) | 1996-12-31 | 2009-03-30 | Reddy S Res Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
JP2001510195A (ja) | 1997-07-16 | 2001-07-31 | ノボ ノルディスク アクティーゼルスカブ | 縮合化1,2,4−チアジアジン誘導体、その調製及び使用 |
CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
EP1173438A1 (en) | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
KR100693771B1 (ko) | 1999-04-28 | 2007-03-12 | 사노피-아벤티스 도이칠란트 게엠베하 | Ppar 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물 |
CZ20013833A3 (cs) | 1999-04-28 | 2002-02-13 | Aventis Pharma Deutschland Gmbh | Deriváty kyselin se dvěma arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují |
WO2000066585A1 (en) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
EP1194146B1 (en) | 1999-06-18 | 2006-07-19 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
AU5784000A (en) | 1999-07-09 | 2001-01-30 | Cohesion Technologies, Inc. | Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof |
JP2003506365A (ja) | 1999-07-29 | 2003-02-18 | イーライ・リリー・アンド・カンパニー | ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン:セロトニンアゴニスト |
CZ2002767A3 (cs) | 1999-09-01 | 2002-06-12 | Aventis Pharma Deutschland Gmbh | Sulfonylkarboxamidové deriváty, způsob jejich přípravy a jejich pouľití jako léčiv |
TW200528436A (en) | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
DE60008921T2 (de) | 1999-12-03 | 2005-01-20 | Astrazeneca Ab | Kristalline form von (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenyl-ethoxy)phenyl]propansäure |
SE9904413D0 (sv) | 1999-12-03 | 1999-12-03 | Astra Ab | Comminuted form |
IL151368A0 (en) | 2000-03-31 | 2003-04-10 | Probiodrug Ag | Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions |
US6770133B2 (en) | 2000-04-25 | 2004-08-03 | Kyorin Pharmaceutical Co., Ltd. | Stable crystal of thiazolidinedione derivative and process for producing the same |
DK1277736T3 (da) | 2000-04-28 | 2007-10-01 | Asahi Kasei Pharma Corp | Hidtil ukendte bicykliske forbindelser |
ES2252230T3 (es) | 2000-05-11 | 2006-05-16 | Bristol-Myers Squibb Company | Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento. |
CA2410597A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
YU91002A (sh) | 2000-06-09 | 2006-05-25 | Aventis Pharma Deutschland | Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka |
TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
RS50864B (sr) | 2000-12-21 | 2010-08-31 | Sanofi-Aventis Deutschland Gmbh. | Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida |
WO2002067912A2 (en) | 2001-02-22 | 2002-09-06 | Smithkline Beecham Corporation | Method for treating ppar gamma mediated diseases or conditions |
DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
KR100915108B1 (ko) | 2001-08-31 | 2009-09-03 | 사노피-아벤티스 도이칠란트 게엠베하 | Ppar-활성화제로서의 디아릴사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물 |
EP1448538A1 (en) * | 2001-11-15 | 2004-08-25 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
DE10215907A1 (de) | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
DE10215908B4 (de) | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
DE10225635C1 (de) | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
US7217727B2 (en) | 2003-04-01 | 2007-05-15 | Eli Lilly And Company | Phospholipase inhibitors |
EP1615900A1 (en) | 2003-04-01 | 2006-01-18 | Eli Lilly And Company | Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors |
DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
BRPI0616465A2 (pt) * | 2005-09-29 | 2011-06-21 | Sanofi Aventis | derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica |
-
2004
- 2004-04-01 EP EP04007879A patent/EP1586573B1/en not_active Expired - Fee Related
- 2004-04-01 DE DE602004004631T patent/DE602004004631D1/de not_active Expired - Lifetime
-
2005
- 2005-02-17 GT GT200500028A patent/GT200500028A/es unknown
- 2005-03-19 PT PT05716233T patent/PT1740583E/pt unknown
- 2005-03-19 WO PCT/EP2005/002950 patent/WO2005097786A1/en active Application Filing
- 2005-03-19 JP JP2007505433A patent/JP2007530612A/ja not_active Abandoned
- 2005-03-19 DE DE602005015204T patent/DE602005015204D1/de active Active
- 2005-03-19 ES ES05716233T patent/ES2329484T3/es active Active
- 2005-03-19 AT AT05716233T patent/ATE435225T1/de not_active IP Right Cessation
- 2005-03-19 KR KR1020067020503A patent/KR20060135857A/ko not_active Application Discontinuation
- 2005-03-19 CN CN200580010743A patent/CN100582104C/zh not_active Expired - Fee Related
- 2005-03-19 EP EP09005458A patent/EP2083006A1/en not_active Withdrawn
- 2005-03-19 CA CA002561627A patent/CA2561627A1/en not_active Abandoned
- 2005-03-19 PL PL05716233T patent/PL1740583T3/pl unknown
- 2005-03-19 RU RU2006138498/04A patent/RU2374243C2/ru not_active IP Right Cessation
- 2005-03-19 EP EP05716233A patent/EP1740583B1/en active Active
- 2005-03-19 DK DK05716233T patent/DK1740583T3/da active
- 2005-03-19 BR BRPI0509517-4A patent/BRPI0509517A/pt not_active IP Right Cessation
- 2005-03-19 AU AU2005231916A patent/AU2005231916A1/en not_active Abandoned
- 2005-03-19 SI SI200530778T patent/SI1740583T1/sl unknown
- 2005-03-19 RS RSP-2009/0391A patent/RS51186B/sr unknown
- 2005-03-19 UA UAA200611486A patent/UA84203C2/ru unknown
- 2005-03-22 PE PE2005000323A patent/PE20060323A1/es not_active Application Discontinuation
- 2005-03-30 DO DO2005000051A patent/DOP2005000051A/es unknown
- 2005-03-30 TW TW094109908A patent/TW200602342A/zh unknown
- 2005-03-30 AR ARP050101221A patent/AR050576A1/es not_active Application Discontinuation
- 2005-03-31 MY MYPI20051461A patent/MY142431A/en unknown
- 2005-04-01 UY UY28837A patent/UY28837A1/es unknown
- 2005-04-01 SV SV2005002071A patent/SV2006002071A/es not_active Application Discontinuation
- 2005-04-01 PA PA20058628701A patent/PA8628701A1/es unknown
-
2006
- 2006-08-15 ZA ZA200606870A patent/ZA200606870B/en unknown
- 2006-08-24 CR CR8572A patent/CR8572A/es not_active Application Discontinuation
- 2006-09-13 IL IL178056A patent/IL178056A0/en unknown
- 2006-09-26 US US11/535,266 patent/US20070179191A1/en not_active Abandoned
- 2006-09-29 MA MA29354A patent/MA28495B1/fr unknown
- 2006-09-29 EC EC2006006892A patent/ECSP066892A/es unknown
- 2006-09-29 TN TNP2006000317A patent/TNSN06317A1/en unknown
- 2006-10-31 NO NO20064981A patent/NO20064981L/no not_active Application Discontinuation
-
2007
- 2007-07-31 HK HK07108322.5A patent/HK1100408A1/xx not_active IP Right Cessation
-
2008
- 2008-06-05 US US12/133,405 patent/US7709509B2/en not_active Expired - Fee Related
- 2008-06-05 US US12/133,408 patent/US20080262052A1/en not_active Abandoned
-
2009
- 2009-09-16 CY CY20091100958T patent/CY1109370T1/el unknown
- 2009-09-16 HR HR20090493T patent/HRP20090493T1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200606870B (en) | Oxadiazolone derivatives as PPAR delta agonists | |
EP2913326B1 (en) | Novel modulators of sphingosine phosphate receptors | |
CN101827832B (zh) | 作为葡糖激酶活化剂的乙酰胺衍生物、其制备方法及医药应用 | |
KR101186386B1 (ko) | S1p 수용체 결합능을 갖는 화합물 및 그 의약 용도 | |
EP1846372B1 (en) | Compounds for inflammation and immune-related uses | |
US20050203119A1 (en) | Dihydropyridine compounds for treating or preventing metabolic disorders | |
RU2378259C2 (ru) | Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции | |
RU2339624C2 (ru) | Производные аминоиндазолов и их применение в качестве ингибиторов киназ | |
CA2616451C (en) | Substituted benzyl derivatives as gsk-3 inhibitors | |
KR20040025915A (ko) | 디펩티딜 펩티다아제 iv의 저해제를 이용한 2형당뇨병의 치료 | |
TWI313265B (en) | Novel bicyclic inhibitors of hormone sensitive lipase | |
EP1879887A2 (fr) | Antagonistes npy, preparation et utilisations | |
RU2007142328A (ru) | Производные тиоксантина в качестве ингибиторов миелопероксидазы | |
BG63487B1 (bg) | Използване на хетероциклени съединения | |
CA2394602A1 (en) | New modulators of dopamine neurotransmission | |
CA2488535A1 (en) | Glucocorticoid receptor ligands for the treatment of metabolic disorders | |
RU2008116581A (ru) | Сульфонамидные производные, как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
RU99105567A (ru) | Производные пропионовой кислоты и их использование | |
US20070010529A1 (en) | Nitrogenous heterocyclic compounds and medical use thereof | |
WO2002085901A8 (en) | Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists) | |
JP5524853B2 (ja) | 肺疾患及び心臓血管疾患を治療するための置換されたベンゾアゾールpde4阻害剤 | |
US20070105836A1 (en) | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders | |
JP2005526696A5 (sr) | ||
IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
EP3138834A1 (en) | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient |